Developing a target treatment for multiple myeloma
Oncopeptides is working to enhance oncology therapies, by creating cytosuperiors of existing basic cytotoxic compounds. Oncopeptides lead compound, named melflufen, is a cytosuperior of the chemotherapeutic alkylator melphalan.Melflufen is currently undergoing Phase II efficacy studies in patients with relapsed and/or refractory multiple myeloma. A family of enzymes that is expressed at very high levels in cancer cells, such as multiple myeloma cells, causes melflufen and its metabolites to accumulate in the diseased cells. This results in partially targeted delivery of the chemotherapeutic compound to the cancer cells, and thereby better treatment of the disease. news2013.08.20
Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients


NEWS: Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients DOWNLOAD

NEWS: Oncopeptides AB appoints Jakob Lindberg as CEO DOWNLOAD

EVENT: Oncopeptides AB Presents the New Anticancer Agent J1 at The American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, USA.

Dana-Farber Cancer Institute, MA, USA is the lead investigator of a Phase II multi-centre clinical trial in multiple myeloma. This is being conducted in both the US and Western Europe. 

If you are interested in finding out more about this trial please email:
After demonstrating proof of efficacy in man, Oncopeptides intends to take melflufen to market through a corporate parnership.

If you would like to discuss business opportunities with Oncopeptides contact our CEO Mr. Jakob Lindberg or our head of Business Development Dr. Björn Hammarberg.